Treatment of Low-Blast Count AML using Hypomethylating Agents

In 2002, the WHO classification reduced the proportion of blasts in the bone marrow (BM) necessary for the diagnosis of acute myeloid leukemia (AML) from 30% to 20%, eliminating the RAEB-t subtype of myelodysplastic syndromes (MDS). However, this AML subtype, defined as low-blast count AML (LBC-AML,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mediterr J Hematol Infect Dis
Autors principals: De Bellis, Eleonora, Fianchi, Luana, Buccisano, Francesco, Criscuolo, Marianna, Maurillo, Luca, Cicconi, Laura, Brescini, Mattia, Del Principe, Maria Ilaria, Di Veroli, Ambra, Venditti, Adriano, Amadori, Sergio, Arcese, William, Lo-Coco, Francesco, Voso, Maria Teresa
Format: Artigo
Idioma:Inglês
Publicat: Università Cattolica del Sacro Cuore 2017
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5499495/
https://ncbi.nlm.nih.gov/pubmed/28698788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4084/MJHID.2017.045
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars